428 Eli Lilly and Company $LLY Shares Sold by Bourne Lent Asset Management Inc.

Bourne Lent Asset Management Inc. lowered its position in Eli Lilly and Company (NYSE:LLY) by 11.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 3,459 shares of the company’s stock after selling 428 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of Bourne Lent Asset Management Inc.’s portfolio, making the stock its 19th largest position. Bourne Lent Asset Management Inc.’s holdings in Eli Lilly and Company were worth $4,002,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the second quarter valued at $13,522,666,000. Jupiter Topco LLC bought a new stake in Eli Lilly and Company during the second quarter valued at $4,667,180,000. Corient Private Wealth LP bought a new stake in Eli Lilly and Company during the second quarter valued at $764,116,000. BlackRock Inc. grew its holdings in Eli Lilly and Company by 1.6% during the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. Finally, State Street Corp grew its holdings in Eli Lilly and Company by 1.7% during the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after acquiring an additional 605,752 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.4%

LLY stock opened at $1,437.46 on Thursday. The stock’s 50 day simple moving average is $1,231.13 and its 200 day simple moving average is $1,106.42. The company has a market cap of $1.35 trillion, a P/E ratio of 46.66, a price-to-earnings-growth ratio of 1.72 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,453.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company’s revenue for the quarter was up 38.6% compared to the same quarter last year. During the same quarter last year, the firm posted $7.02 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 35.67 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Top Eli Lilly and Company Stories

These are some of the LLY stories that stood out recently:

• Positive Sentiment: Foundayo, Lilly’s GLP-1 weight-loss pill, was reported to have shown substantial improvement in sleep apnea, adding to the potential uses of the company’s obesity pipeline. Article: Foundayo and sleep apnea
• Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook
• Negative Sentiment: The FDA is requiring GLP-1 drugmakers to add a warning about rare NAION-related vision loss. Zepbound is among the medicines affected, creating a potential safety concern for Lilly’s key product category. Article: FDA warning on GLP-1 drugs

Insider Activity

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Berenberg Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a research report on Tuesday, September 15th. Morgan Stanley boosted their price target on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Citigroup boosted their price target on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research note on Friday, October 30th. TD Cowen reaffirmed a “buy” rating and set a $1,250.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $1,650.00 price objective on shares of Eli Lilly and Company in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,416.64.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.